Actively Recruiting
Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis
Led by University Hospital, Lille · Updated on 2025-12-26
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Systemic sclerosis (SSc) is a complex disease with varying severity and poorly understood causes. This research investigates the diversity of fibroblasts and immune cells in the skin of patients with SSc, focusing on their molecular characteristics. The role of B lymphocytes and their interaction with fibroblasts, which produce excess collagen, is a key part of this study, aiming to better understand disease mechanisms. Participants include patients who meet specific criteria for systemic sclerosis. The study involves collecting blood samples and skin biopsies from these participants. Both patients with SSc and healthy subjects are included to compare findings. This is an observational study that does not involve experimental treatments. Participants will undergo single-cell RNA sequencing analysis of their skin and blood samples at the time of inclusion. The study measures molecular signatures of cells to explore disease pathways. The total duration of participation is not specified, but the primary and secondary outcomes focus on detailed cellular analysis at enrollment. The study is sponsored by the University Hospital, Lille.
CONDITIONS
Brief Title
Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Man or woman over 18 years of age
- Diagnosis of systemic sclerosis meeting the ACR-EULAR 2013 criteria
- Signed informed consent
- Being insured
You will not qualify if you...
- Overlap syndrome with another connective tissue disease
- Immunosuppressive treatment within the past 12 months
- Current corticosteroid therapy dose of 10 mg/day or higher
- Protected minors or adults
- Pregnant or breastfeeding women
- Deprived of liberty
- Emergency situations
- Refusal or inability to give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At inclusion
Participants undergo blood sampling and skin biopsy for transcriptomic analysis.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Hop Claude Huriez Chu Lille
Lille, France, 59037
Actively Recruiting
Research Team
D
David Launay, MD,PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here